Kyndryl Named a Leader in IDC MarketScape Worldwide Hybrid IT Consulting and Integration Services 2025
The IDC MarketScape is a vendor assessment tool, providing in-depth quantitative and qualitative technology market assessments of the competitive fitness of suppliers in a given market. This IDC MarketScape report evaluated twelve service providers with broad portfolios and global scale and positioned Kyndryl as a Leader in hybrid IT consulting and integration services.
"With Kyndryl's 30+ years of business and IT experience, its best practices, capabilities, methodologies and culture, the company is well positioned as a Leader and trusted advisor in hybrid IT services," said Leslie Rosenberg, Research Vice President, Network Life Cycle and Infrastructure Services at IDC. "Kyndryl's ability to understand their customers' business objectives coupled with its capabilities for insights across the IT estate was viewed favorably among customers and study participants, which rated Kyndryl highly for its ability to increase business agility, accelerate speed of deployment, and improve compliance."
"Kyndryl is honored to be recognized as a Leader in hybrid IT modernization, which we believe acknowledges our expertise and the value we bring to customers," said Nicolas Sekkaki, Global Cloud Practice Leader at Kyndryl. "As the growing complexity of technology environments hinders the ability to drive modernization initiatives, organizations increasingly need support in transforming their IT. With our deep expertise and thousands of highly skilled professionals, we can help customers improve operational efficiency, capitalize on automation and AI, and drive better business outcomes from their hybrid IT environments."
The IDC MarketScape report noted that, "Kyndryl's ability to understand the customers' business objectives coupled with the company's capabilities for insights across the IT estate was viewed favorably among customers and study participants who rated Kyndryl highly for its ability to increase business agility, accelerate speed of deployment, and improve compliance." A Kyndryl customer stated, "Recommendations are based on deep understanding of our business through weekly meetings," and another customer found Kyndryl to be "progressive, reliable, modern, and efficient."
Learn more about Kyndryl Hybrid IT Modernization.
About IDC MarketScapeIDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of vendors can be meaningfully compared. The framework also provides buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective. For more information, visit www.idc.com.
About Kyndryl Kyndryl (NYSE: KD) is a leading provider of mission-critical enterprise technology services offering advisory, implementation and managed service capabilities to thousands of customers in more than 60 countries. As the world's largest IT infrastructure services provider, the company designs, builds, manages and modernizes the complex information systems that the world depends on every day. For more information, please visit: www.kyndryl.com.
Kyndryl Press Contactpress@kyndryl.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kyndryl-named-a-leader-in-idc-marketscape-worldwide-hybrid-it-consulting-and-integration-services-2025-302451806.html
SOURCE Kyndryl
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
D-Wave Quantum (QBTS) Gets Bullish Reco, Jumps 13.78%
We recently published . D-Wave Quantum Inc. (NYSE:QBTS) is one of the top-performing companies on Thursday. D-Wave Quantum rallied for a fourth straight day on Thursday, jumping 13.78 percent to close at $19.24 apiece as investors gobbled up shares following an analyst's recommendation to own its shares. In the latest episode of the Mad Money show, host and former hedge fund manager Jim Cramer advised a caller to own shares in D-Wave Quantum Inc. (NYSE:QBTS). '[In just] one headline, one little story, that stock goes up 10 more points…and D-Wave has the ability to do that because it is actually a real company,' he said. A modern computer datacenter, running an advanced quantum computer system. In other news, D-Wave Quantum Inc. (NYSE:QBTS) is expected to announce the results of its second quarter earnings in the second week of August 2025. D-Wave Quantum Inc. (NYSE:QBTS) recently earned an 'outperform' rating from Cantor Fitzgerald with a price target of $20, saying that quantum computing is 'one of the most highly coveted technical milestones with significant economical implications.' While we acknowledge the potential of QBTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Oscar Health (OSCR) Falters on UBS' 'Sell' Reco
We recently published . Oscar Health, Inc. (NYSE:OSCR) is one of the worst-performing companies on Thursday. Oscar Health fell by 9.64 percent on Thursday to close at $13.87 apiece as investor sentiment was dampened by analysts' pessimistic views about the insurance industry. In a market note recently, investment firm UBS recommended investors to sell their shares in Oscar Health, Inc. (NYSE:OSCR), a revision from the 'neutral' stance previously amid the growing instability of the Affordable Care Act. The brokerage firm also lowered its price target for the stock to $11 from $15 previously, marking a 20.7 percent downside from its latest closing price. According to UBS, it now expects enrollments to its programs to drop by 30 percent next year, worse than its previous estimate of 18 percent. A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. Further dampening sentiment, insurance counterpart Elevance Health reported a 24.2-percent drop in net income during the second quarter of the year, while another insurance firm, Centene Corp., withdrew its 2025 earnings forecast earlier this month due to an expected slump in its revenues from commercial plans under the ACA or Obamacare. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9%
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial growth with the surging prevalence of chronic diseases and advancements in nuclear imaging techniques. The technetium-99m market is expected to reach US$6.29 billion by 2031 from US$ 4.61 billion in 2024; it is anticipated to register a CAGR of 3.9% during the forecast period. Technetium-99m (Tc-99m) is an extensively used radioactive isotope for diagnostic imaging in nuclear medicine. It holds the position of being the most common medical radioisotope worldwide and is used for over 40,000 imaging procedures daily in the US. To explore the valuable insights in the Technetium-99m Market report, you can easily download a sample PDF of the report - Some of the reasons behind Tc-99m's medical popularity are its ideal imaging properties, such as a short half-life of about six hours, suitable gamma energy, as well as providing a low radiation dose, giving it the capability to image organs such as the brain, heart, bones, lungs, kidneys, thyroid, and liver. The development of this market is sustained by increasing demand for Tc-99m-based radiopharmaceuticals in cardiovascular imaging and cancer detection, along with other clinical applications. North America stands as a huge market due to the advanced healthcare infrastructure and high rate of chronic diseases. Asia Pacific is growing fast owing to healthcare infrastructure investments and a focus on advanced diagnostics. The report carries an in-depth analysis of market trends, key players, and future opportunities. The technetium-99m market study focuses on an array of technologies that are expected to fuel the demand in the coming years. For Detailed Technetium-99m Market Insights, Visit: Overview of Report Findings Increasing Chronic Diseases Prevalence: The increase in prevalence of chronic diseases is a much stronger driver for the global Technetium-99m (Tc-99m) market. Tc-99m is the most important radioisotope used in more than 80% of nuclear medicine procedures in the world, mostly used in SPECT scanning for the diagnosis of cancer, cardiovascular diseases, and neurological disorders. According to the International Agency for Research on Cancer, the prevalence of cancer is high worldwide. It is estimated that there were 19.3 million cancer cases globally in 2020, and the number is expected to reach ~30.2 million by 2040. With an increase in the incidence of chronic diseases due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for higher diagnostic imaging techniques rises correspondingly. Such a scenario is evident in Asia Pacific, where chronic diseases such as diabetes and cardiovascular diseases are rising. Health care providers are thus increasingly adopting technetium-based imaging techniques for early diagnosis and for planning of treatment. This rise in demand is favoring the development of the Tc-99m market. Soaring Technological Advancements: Technological discoveries open a whole new set of vistas for the Technetium-99m (Tc-99m) market by making nuclear imaging more efficient, accurate, and accessible. At the forefront of these discoveries are radiopharmaceutical production technologies that include cyclotron-based Tc-99m production that nullifies the need for assessing the aged nuclear reactors and thereby assures more stable Tc-99m supplies. In addition, imaging instrument improvement, mainly within SPECT and hybrid imaging equipment such as SPECT/CT, have increased the resolution and diagnostic ability, thereby increasing Tc-99m's clinical utility. Further, automation in radiopharmacy and simultaneous integration of digital imaging workflows minimize human errors and maximize safety and efficiency. Artificial intelligence and machine learning are further being explored and used for image analysis to provide enhanced and more rapid diagnostic capabilities. Thus, these technological advancements account for the expanding sphere of clinical applications of Tc-99m while reducing operational costs in nuclear medicine, which include its accessibility to emerging markets. Several innovations and various avenues for research, investment, and patient care are being formed in the Tc-99m market. Stay Updated on The Latest Technetium-99m Market Trends: Geographical Insights: In 2024, North America led the technetium-99m market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Market Segmentation By application, the market is categorized into cardiovascular, bone scan, respiratory, tumor imaging, and others. The bone scan segment accounted for the largest share of the market in 2024. Based on end user, the market is segmented into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest share of the market in 2024. The technetium-99m market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: Lantheus Medical Imaging Inc., Curium, Jubilant Pharma Company, NorthStar Medical Radioisotopes LLC, Sun Pharmaceutical Industries Inc., Advancing Nuclear Medicine, NTP Radioisotopes SOC Ltd, Northwest Medical Isotopes LLC, and SHINE Technologies LLC are major companies operating in the market. Trending Topics: Emergence of Hybrid Imaging Techniques, Advancements in Radiopharmaceutical Development, and Sustainability and Cost-Effectiveness Initiatives. Purchase Premium Copy of Global Technetium-99m Market Size and Growth Report (2021-2031) at: Global Headlines on Technetium-99m Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection). BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone. IAEA Launches Research Project to Develop New Technetium-99m Radiopharmaceuticals. Conclusion The demand for technetium-99m is expanding at a rapid pace with increasing requirements for advanced diagnostic imaging, primarily for areas such as oncology, cardiology, and neurology. The largest market for Technetium-99m is North America followed by the easy availability of radiopharmaceuticals and higher average cost of kit for Tc-99m. The technetium-99m market in Asia Pacific is segmented into Japan, China, and India and is also expected to grow at the fastest CAGR due to the increasing investments in improving healthcare infrastructure and rising focus on advanced diagnostics. The development of imaging, such as SPECT and hybrid SPECT/CT systems, is becoming more accurate and reliable in Tc-99m using diagnostics. Furthermore, ongoing development of production technologies, such as non-reactor-based ones address Mo-99 supply chain issues, the progenitor isotope for Tc-99m. Thus, continuous advancements in imaging instruments and manufacturing technologies and government initiatives for bettering nuclear medication facilities are expected to drive the market during the forecast period. The report from The Insight Partners lists several stakeholders—including radiopharmaceutical manufacturers, medical equipment suppliers, healthcare providers, and regulatory bodies—along with valuable insights to navigate this evolving market landscape and unlock new opportunities successfully. For More Latest Life Sciences Research Reports & Industry Analysis - Trending Related Reports: Bone Scan Market Growth, Top Key Players, and Regional Forecast by 2031 Respiratory Disposable Devices Market Size, Trends, Shares, and Forecast – 2031 Respiratory Medical Device Market Size, Trends, Shares, and Forecast – 2031 Respiratory Drug Delivery Devices Market Size, Trends, Shares, and Forecast - 2031 The Tumor Embolization Market Size is expected to register a CAGR of 8.9% from 2025 to 2031 The Heart Tumor Market Size is expected to register a CAGR of 8.0% from 2025 to 2031 The Tumor Ablation Market Size is expected to register a CAGR of 12.5% from 2025 to 2031 The Respiratory Protection Equipment Market Size is expected to register a CAGR of 6.8% from 2025 to 2031 Respiratory Medical Device Professional Market Size Drivers, Opportunities, Trends, and Forecasts by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Press Release - Logo - View original content: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
